Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
0.2641
+0.0167 (6.75%)
At close: May 12, 2025, 4:00 PM
0.2620
-0.0021 (-0.80%)
After-hours: May 12, 2025, 6:23 PM EDT
Cellectar Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Cellectar Biosciences.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for Cellectar Biosciences is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +4,443.73% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $14 | Buy | Reiterates | $14 | +5,201.02% | Oct 11, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +10,502.04% | Mar 28, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +4,443.73% | Mar 28, 2024 |
Financial Forecast
Revenue This Year
n/a
from 96.53M
Revenue Next Year
n/a
EPS This Year
-0.65
from -1.40
EPS Next Year
-0.71
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.66 | -0.63 | -0.60 | ||
| Avg | -0.65 | -0.71 | -0.72 | ||
| Low | -0.64 | -0.84 | -0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.